Pelish Henry E.

CSO Pelish Henry E. sold 35,104 shares for $3.4M across 6 transactions on 2026-03-12/13.

Pelish Henry E., Chief Scientific Officer of Nuvalent, executed 6 separate sales totaling 35,104 shares for $3,442,856.43, reducing his holdings by 34.9% in a single filing. The sales occurred across two trading days at prices ranging from $97.79 to $99.71, with a blended average of $98.08, near the current price of $99.52. His prior 5 trades at NUVL show a 4-of-5 pattern of well-timed sells at the 90-day mark (negative returns following sales), suggesting a track record of selling ahead of declines; his cross-ticker history shows a 90.91% well-timed rate with an average 90-day return of -9.3% after sells. The company posted negative net income of $-122,437,000.00 for the most recent full fiscal year, and the stock is trading 11.1% below its 52-week high.

CSO Pelish Henry E. sold 14,205 shares of NUVL at $90.04 (−$1.3M), reducing holdings 17.7%; prior 5 NUVL sells all well-timed at 90-day mark despite unprofitability.

Pelish Henry E., Chief Scientific Officer, sold 14,205 shares at $90.04 on 2025-10-15, totaling $1,279,018.20, reducing his stake from 80,168 to 65,963 shares. His prior five transactions at NUVL, all executed on 2024-09-16, demonstrated consistent well-timed execution at the 90-day mark, with negative 90-day returns ranging from −6.8% to −11.0%. His cross-ticker track record shows a 100.00% well-timed sell rate across 10 prior sales. The company reported a net loss of $99,653,000.00 over its most recent full fiscal year, establishing a context of underlying unprofitability. This sale by a Chief Scientific Officer—a role typically deep in R&D strategy—combined with a pattern of consistently well-timed exits, merits attention as a potential signal about insider conviction in the company's near-term trajectory.

Chief Scientific Officer Pelish Henry E. sells 32,795 shares (49.6% of holdings) across 10 transactions for $3,244,140.05 on 2024-09-16.

Pelish Henry E., Chief Scientific Officer, executed 10 separate sales totaling 32,795 shares for $3,244,140.05 on a single date (2024-09-16), reducing his stake by approximately 49.6% from 66,095 shares to 33,300 shares. The blended average price across all transactions was $98.92, and the stock currently trades at $102.63, near its 52-week high of $112.17. The transaction occurred in the context of strong recent price momentum—the stock has appreciated 37.1% over the prior 30 days and 30.9% over 90 days. However, the company reported a net loss of $57,166,000.00 over its most recent fiscal year with a market cap of $321,168,679.92, indicating Nuvalent remains unprofitable. The substantial single-day liquidation of roughly half his holdings by the Chief Scientific Officer merits investor attention given the company's ongoing losses and the timing relative to the stock's recent rally.